These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 30961835)

  • 1. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
    Castells M; Butterfield J
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1097-1106. PubMed ID: 30961835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cell disorders: Protean manifestations and treatment responses.
    Chen M; Kim A; Zuraw B; Doherty TA; Christiansen S
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):128-130. PubMed ID: 29604336
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell activation disorders.
    Akin C
    J Allergy Clin Immunol Pract; 2014; 2(3):252-7.e1; quiz 258. PubMed ID: 24811013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
    Butterfield JH; Ravi A; Pongdee T
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
    Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
    Butterfield JH; Weiler CR
    Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H1-antihistamines for primary mast cell activation syndromes: a systematic review.
    Nurmatov UB; Rhatigan E; Simons FE; Sheikh A
    Allergy; 2015 Sep; 70(9):1052-61. PubMed ID: 26095756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insect Sting Anaphylaxis-Or Mastocytosis-Or Something Else?
    Golden DBK; Carter MC
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1117-1123. PubMed ID: 30961837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022.
    Butterfield JH
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1974-1984. PubMed ID: 35346887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
    Butterfield JH
    Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of mastocytosis.
    Tharp MD
    Am J Med Sci; 1985 Mar; 289(3):119-32. PubMed ID: 2579553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent PGD
    Butterfield JH; Singh RJ
    Prostaglandins Other Lipid Mediat; 2021 Aug; 155():106563. PubMed ID: 34029712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast cell activation syndrome: a review.
    Frieri M; Patel R; Celestin J
    Curr Allergy Asthma Rep; 2013 Feb; 13(1):27-32. PubMed ID: 23179866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Systemic mastocytosis].
    Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
    Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence.
    Hamilton MJ
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):469-481. PubMed ID: 30007464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mast cell activation syndrome].
    Brockow K
    Hautarzt; 2013 Feb; 64(2):102-6. PubMed ID: 23385621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful mast-cell-targeted treatment of chronic dyspareunia, vaginitis, and dysfunctional uterine bleeding.
    Afrin LB; Dempsey TT; Rosenthal LS; Dorff SR
    J Obstet Gynaecol; 2019 Jul; 39(5):664-669. PubMed ID: 30964355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.